Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

80.46CHF
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
CHF80.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,961,484
52-wk High
CHF88.30
52-wk Low
CHF72.45

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.08
Market Cap(Mil.): CHF208,802.41
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.80
Yield (%): 3.51

Financials

  Industry Sector
P/E (TTM): -- 32.45 17.28
EPS (TTM): -- -- --
ROI: -- 14.04 35.61
ROE: -- 15.50 17.17

MEDIA LINK-Novartis CEO is using data science to revolutionize its drug-development pipeline -WSJ

Note: Reuters has not verified this story and cannot vouch for its accuracy. (New York Newsroom)

Feb 19 2018

Novartis readies to auction U.S. generic pills business: sources

Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

Feb 16 2018

CORRECTED-Novartis readies to auction U.S. generic pills business -sources

Feb 16 Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

Feb 16 2018

BRIEF-Novartis forms alliance for treating infectious diarrheal disease

* NOVARTIS FORMS ALLIANCE TO DEVELOP MEDICINES FOR TREATING INFECTIOUS DIARRHEAL DISEASE

Feb 14 2018

Novartis gains U.S. approval for delayed MS drug

ZURICH Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.

Feb 13 2018

UPDATE 2-Novartis gains U.S. approval for delayed MS drug

* U.S. pricing pressure weighing on Sandoz (Adds Teva comment, share price reaction)

Feb 13 2018

Novartis gets U.S. approval for bigger dose Glatopa MS treatment

ZURICH, Feb 13 Novartis's Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients.

Feb 13 2018

Greek PM wants politicians investigated in alleged Novartis bribery case

ATHENS/ZURICH Greece's prime minister urged parliament on Monday to probe politicians in an alleged drug bribery case, while Swiss drugmaker Novartis promised to take action if an investigation found unethical conduct.

Feb 12 2018

Novartis promises fast, decisive action if wrongdoing found in Greece

ZURICH, Feb 12 Swiss drugmaker Novartis has promised to take "fast and decisive action" should an investigation into alleged bribery in Greece find that its managers engaged in unethical or illegal conduct.

Feb 12 2018

Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

LONDON, Feb 8 GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division.

Feb 08 2018

Earnings vs. Estimates